Tumor Marker Testing Market Report 2025

This tumor marker testing market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The tumor marker testing market size has grown strongly in recent years. It will grow from $17.18 billion in 2024 to $18.6 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing cancer prevalence, rising focus on research and development, rising public awareness of cancer screenings, improved healthcare infrastructure, and an aging population.

The tumor marker testing market size is expected to see strong growth in the next few years. It will grow to $25.27 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing awareness of early cancer detection, increasing funding for cancer research, expansion of personalized medicine, increased healthcare expenditure, and improved insurance coverage. Major trends in the forecast period include technological advancements, product innovation, advancement in diagnostic technologies, innovative testing solutions, and increasing strategic collaborations.

The growth of the tumor marker testing market is expected to be driven by the rising prevalence of cancer. Cancer is a disease marked by the uncontrolled growth of abnormal cells that can invade nearby tissues and spread throughout the body via the blood and lymphatic systems. The increase in cancer rates is attributed to factors such as an aging population, greater environmental exposures, lifestyle changes, and advancements in detection and diagnosis. Tumor marker testing is used to diagnose cancer, monitor treatment responses, and detect recurrences by measuring specific substances produced by cancer cells. For example, a report from the American Cancer Society in January 2023 noted that there were 1,958,310 new cancer cases and 609,820 cancer deaths in the United States. Additionally, the National Library of Medicine projected in May 2021 that the global cancer burden would reach 28.4 million cases by 2040, representing a 47% increase from 2020, with a substantial number of deaths. This increasing prevalence of cancer is driving the growth of the tumor marker testing market.

Companies in the tumor marker testing market are focusing on developing advanced tests, such as molecular testing solutions, to stay competitive. Molecular testing solutions are sophisticated diagnostic methods that analyze genetic material (DNA or RNA) to detect mutations, pathogens, or specific biomarkers at a molecular level. For instance, in April 2024, RGCC International GmbH, a Swiss company specializing in personalized cancer treatment, introduced Onco-D-clare, an innovative cancer detection test. This test enables early cancer detection before symptoms appear by combining molecular biology with artificial neural networks. Onco-D-clare isolates peripheral blood mononuclear cells from blood samples and performs a comprehensive gene expression analysis across more than 90 genes.

In June 2023, Quest Diagnostics, a US-based clinical laboratory, acquired Haystack Oncology for $300 million. This acquisition is intended to improve cancer diagnostics by integrating advanced minimal residual disease (MRD) testing technology. Furthermore, it not only enhances Quest's diagnostic capabilities but also seeks to offer more personalized and effective cancer care solutions through innovative liquid biopsy technology. Haystack Oncology is a biotechnology company based in the United States.

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV.

North America was the largest region in the tumor marker testing market in 2024. The regions covered in the tumor marker testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor marker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tumor marker testing involves detecting specific substances, often proteins, that are produced by cancer cells or by the body in response to cancer. These tests are used for diagnosing cancer, monitoring treatment progress, and checking for recurrence. Typically, the tests are conducted on blood, urine, or tissue samples.

Key products in tumor marker testing include biochemical markers, oncogenes, growth factors, hormones, colony-stimulating factors, lymphokines, and immunohistochemical stains, among others. Biochemical markers are measurable substances in the body, such as proteins or enzymes, that indicate biological or pathological processes and are used for diagnosing or tracking diseases. Tumor marker testing is conducted using methods such as screening, imaging, theranostics, and sigmoidoscopy. It is utilized in various settings including hospitals, commercial or private laboratories, physician offices or group practices, cancer clinics, and ambulatory care centers.

The tumor marker testing market research report is one of a series of new reports that provides tumor marker testing market statistics, including the tumor marker testing industry's global market size, regional shares, competitors with a tumor marker testing market share, detailed tumor marker testing market segments, market trends and opportunities, and any further data you may need to thrive in the tumor marker testing industry. This tumor marker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tumor marker testing market consists of revenues earned by entities by providing services such as genetic testing, prostate-specific antigen (PSA) tests, and dehydrogenase (LDH) tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor marker testing market also includes sales of test kits, instrumentation, consumables, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.